Diabetic macular edema (DME) is a leading cause of vision loss in patients with diabetic retinopathy. The pathophysiology of DME involves multiple mechanisms, including vascular endothelial growth factor (VEGF) overexpression and chronic inflammation. Two major pharmacologic approaches are widely used for DME management:

   Anti-VEGF Therapy (Aflibercept)

          Aflibercept is a recombinant fusion protein that binds VEGF-A, VEGF-B, and placental growth factor (PlGF), thereby inhibiting neovascularization and vascular leakage.

      It has been established as a first-line therapy for center-involving DME due to its proven efficacy in improving visual acuity (BCVA) and reducing central macular thickness (CMT).

          However, frequent injections (every 4-8 weeks) are required to maintain efficacy, leading to increased treatment burden and patient non-compliance.

2      Corticosteroid Therapy (Dexamethasone Implant - Ozurdex)

        The dexamethasone intravitreal implant (Ozurdex) provides sustained-release corticosteroid therapy, targeting the inflammatory component of DME. It reduces cytokine-mediated vascular permeability and stabilizes the blood- retinal barrier. Compared to anti-VEGF agents, Ozurdex has a longer duration of action, potentially reducing the number of injections required .However, side effects such as intraocular pressure (IOP) elevation and cataract progression are concerns, especially in phakic patients.

        In DME, intravitreal corticosteroids, been traditionally used as second-line     treatment, due to the risk of intraocular pressure increase and cataract-related adverse events.

        However, attention has recently been focused on the primary or early use of intravitreal corticosteroids, due to growing evidence of the crucial role of inflammation in the pathogenesis of DME.

      Furthermore, intravitreal steroid implants offer the additional advantage of a longer duration of action compared to anti-vascular endothelial growth factor agents (anti-VEGF).